GTXI GTx Inc.

1.06
-0.45  -30%
Previous Close 1.51
Open 1.03
Price To Book 0.82
Market Cap 25494955
Shares 24,051,844
Volume 2,153,683
Short Ratio
Av. Daily Volume 361,852

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2, 2009.
Toremifene
Reduce fractures in men with prostate cancer
Noted August 14, 2017 that trial will not continue due to insufficient clinical benefit response (CBR).
Enobosarm
Breast cancer - advanced AR+ TNBC
Phase 2 data released September 21, 2018 did not meet primary endpoint.
Enobosarm
Postmenopausal women with stress urinary incontinence (SUI)
Phase 2 updated open-label data presented May 18, 2018 at American Urological Association (AUA) Meeting.
Enobosarm - open label
Stress urinary incontinence (SUI)